Technology Transfer News
Technology transfer - meaning the transfer of research results to industry - can take place in various ways. Founding a spin-off is a very efficient way of transferring or commercialising a technology developed at PSI to industry. In recent years, PSI has founded a number of such spin-offs from various research areas. Even years later, PSI is still in close contact with most of its spin-offs, from which both sides can benefit. The company "SwissNeutronics AG", based in Klingnau, is the oldest PSI spin-off and was spun off as early as 1999. For more than 20 years, SwissNeutronics and the PSI have repeatedly worked together successfully on various projects and can mutually benefit from synergy effects.
After the topping-out ceremony of the Park Innovaare took place in autumn 2021 as an important milestone, construction continues to progress according to plan. From 2024, companies and researchers will work together at one place.
Around two and a half years have now passed since the groundbreaking ceremony for Park Innovaare was held in 2019. Since then, the project has taken shape as planned and is well on schedule, despite various challenges such as a pandemic or shortage of raw materials. In the meantime, the scaffolding has been removed from the buildings and the focus of further construction work is on the interior fittings. With more than 35,000 m2 of space, the Park Innovaare offers laboratories, clean rooms and workshops, as well as offices, co-working spaces and meeting rooms - a versatile range of facilities for a wide variety of needs. There will also be meeting rooms to promote exchange between research and industry, as well as a restaurant.
The first tenants, including PSI as the main tenant, are expected to be able to move in at the beginning of 2024. Around 70% of the space has already been let; further customer acquisition is currently underway so that the Park Innovaare ecosystem can be further expanded in the coming months and other companies can benefit from direct access and exchange with the PSI by locating on site.
ANAXAM offers industry access to advanced analytical methods using neutron and synchrotron radiation (X-rays) at the Paul Scherrer Institute (PSI)
In a wide range of application fields, ANAXAM supports industry and SMEs in improving materials, products and processes in a wide range of application fields, thus strengthening their competitiveness and innovative power.
The event is organised and held jointly with KMU Swiss (event language: German).
Register for the event and learn how your company can also benefit from collaborating with ANAXAM:
When: 28th April 2022, starting at 4:00 pm
Where: PSI West, Auditorium
PSI scientists have developed a ground-breaking achromatic lens for X-rays which facilitates the glimpse into the nanoworld. This allows the X-ray beams to be accurately focused on a single point even if they have different wavelengths. Soon, the newly developed lens will also be used in industry.
What started as an idea a few years ago has been established itself at PSI as a valuable funding instrument for talented researchers or engineers: the PSI Founder Fellowship (PSIFF for short). It is aimed at researchers with an entrepreneurial spirit and is supported by UBS.
This year, two fellows from PSI are starting the program: Dr Sebastian Gliga from the "Photon Science Division" and Dr Lars Gerchow from the research division "Neutrons and Muons" convinced the PSIFF jury with their business ideas. We warmly congratulate the two budding young entrepreneurs and look forward to working with them!
This year's KMU Swiss Symposium will take place in Baden, Kt. Aargau, on 17 March - we are pleased to be physically present again this year!
The KMU Swiss Symposium offers a platform for exchange and inspiration - this is made possible by exciting presentations, various booths with innovative projects and networking.
Federal Councillor Viola Amherd will also be a guest in Baden on 17 March and will give the opening speech, followed by other top-class speakers, including Nina Suma, Managing Director of the Baden thermal spa "Fortyseven", neuroscientist Claudia Thali, Thomas Boyer, CEO of Groupe Mutuel and Guido Konrad, Managing Director of Varian Medical Imaging Labs.
PSI will be there - visit us at our joint booth with the Hightech Zentrum Aargau and find out more about how we can support industry and SMEs with their technical challenges and innovation processes.
Detailed information and registration for the event at:
Researchers at the Paul Scherrer Institute PSI and the University of Basel have developed a rapid test for Covid-19. Its novel functional principle promises reliable and quantifiable results concerning a patient's Covid-19 disease and its course – as well as evidence concerning other diseases and Covid variants that may be present.
Now a new test developed at PSI – which, unlike antigen tests, does not directly detect components of the virus, but rather the antibodies the immune system produces in response to the infection –promises to bring substantially more predictive power to rapid testing. It is just as inexpensive, quick, and easy to use, and it can also be used to simultaneously identify a variety of pathogens, such as those responsible for the flu.
Before it can go into widespread use, however, it still must undergo further testing and optimisation.
PSI researchers, together with researchers from Cornell University in New York State, have identified a composite material that could integrate quantum devices into semiconductor technology, making electronic components significantly more powerful. Among the most important challenges currently facing semiconductor electronics are improvements that would increase data transmission bandwidth, energy efficiency and information security. The incorporation of quantum effects could provide a new breakthrough and could be trend-setting for the semiconductur-industry.
Researchers at the Paul Scherrer Institute PSI have tested various methods to check how effective they are in combatting certain types of cancer. They found a combination of two preparations to be much more effective than treatment with just one of the two active substances. This is particularly important for the treatment of modular thyroid carcinomas. If the results obtained so far are confirmed in future studies, this therapy could be available to the general public in a few years.